Drugs / Interferon-β-1
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01403376 Comparator | Sep 2011 → Jan 2012 | multiple sclerosis | Sanofi | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Interferon-β-1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01403376 ↗ |
| Known as | IFN-β-1 | “Influenza vaccine in participants treated with a stable dose of Interferon-β-1 (IFN-β-1) for at least 6 months” NCT01403376 ↗ |
| Route | Intramuscular | “either intramuscular or subcutaneous injection” NCT01403376 ↗ |
| Route | Subcutaneous | “either intramuscular or subcutaneous injection” NCT01403376 ↗ |